Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency

  1. Lang-Meli, Julia
  2. Fuchs, Jonas
  3. Mathé, Philipp
  4. Ho, Hsi-en
  5. Kern, Lisa
  6. Jaki, Lena
  7. Rusignuolo, Giuseppe
  8. Mertins, Susanne
  9. Somogyi, Vivien
  10. Neumann-Haefelin, Christoph
  11. Trinkmann, Frederik
  12. Müller, Michael
  13. Thimme, Robert
  14. Umhau, Markus
  15. Quinti, Isabella
  16. Wagner, Dirk
  17. Panning, Marcus
  18. Cunningham-Rundles, Charlotte
  19. Laubner, Katharina
  20. Warnatz, Klaus ORCID logo

Download
s10875-021-01193-2.pdf 935,89KB
WeightNameValue
1000 Titel
  • Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency
1000 Autor/in
  1. Lang-Meli, Julia |
  2. Fuchs, Jonas |
  3. Mathé, Philipp |
  4. Ho, Hsi-en |
  5. Kern, Lisa |
  6. Jaki, Lena |
  7. Rusignuolo, Giuseppe |
  8. Mertins, Susanne |
  9. Somogyi, Vivien |
  10. Neumann-Haefelin, Christoph |
  11. Trinkmann, Frederik |
  12. Müller, Michael |
  13. Thimme, Robert |
  14. Umhau, Markus |
  15. Quinti, Isabella |
  16. Wagner, Dirk |
  17. Panning, Marcus |
  18. Cunningham-Rundles, Charlotte |
  19. Laubner, Katharina |
  20. Warnatz, Klaus |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-12-10
1000 Erschienen in
1000 Quellenangabe
  • 42(2):253-265
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10875-021-01193-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664001/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Patients with primary antibody deficiency are at risk for severe and in many cases for prolonged COVID-19. Convalescent plasma treatment of immunocompromised individuals could be an option especially in countries with limited access to monoclonal antibody therapies. While studies in immunocompetent COVID19 patients have demonstrated only a limited benefit, evidence for the safety, timing, and effectiveness of this treatment in antibody-deficient patients is lacking. Here, we describe 16 cases with primary antibody deficiency treated with convalescent plasma in four medical centers. In our cohort, treatment was associated with a reduction in viral load and improvement of clinical symptoms, even when applied over a week after onset of infection. There were no relevant side effects besides a short-term fever reaction in one patient. Longitudinal full-genome sequencing revealed the emergence of mutations in the viral genome, potentially conferring an antibody escape in one patient with persistent viral RNA shedding upon plasma treatment. However, he resolved the infection after a second course of plasma treatment. Thus, our data suggest a therapeutic benefit of convalescent plasma treatment in patients with primary antibody deficiency even months after infection. While it appears to be safe, PCR follow-up for SARS-CoV-2 is advisable and early re-treatment might be considered in patients with persistent viral shedding.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Common variable immunodeficiency
lokal Antibodies, Viral/immunology [MeSH]
lokal COVID-19/immunology [MeSH]
lokal Aged [MeSH]
lokal Plasma/immunology [MeSH]
lokal COVID-19/therapy [MeSH]
lokal Original Article
lokal Antibodies, Neutralizing/immunology [MeSH]
lokal Male [MeSH]
lokal SARS-CoV-2/immunology [MeSH]
lokal Child [MeSH]
lokal Immunization, Passive/methods [MeSH]
lokal SARS-CoV-2
lokal Primary immunodeficiencies
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Primary Immunodeficiency Diseases/immunology [MeSH]
lokal Adult [MeSH]
lokal Antibodies, Monoclonal/immunology [MeSH]
lokal Humans [MeSH]
lokal Middle Aged [MeSH]
lokal COVID-19
lokal Inborn errors of immunity
lokal Virus Shedding/immunology [MeSH]
lokal Young Adult [MeSH]
lokal Convalescent plasma
lokal Hypogammaglobulinemia
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TGFuZy1NZWxpLCBKdWxpYQ==|https://frl.publisso.de/adhoc/uri/RnVjaHMsIEpvbmFz|https://frl.publisso.de/adhoc/uri/TWF0aMOpLCBQaGlsaXBw|https://frl.publisso.de/adhoc/uri/SG8sIEhzaS1lbg==|https://frl.publisso.de/adhoc/uri/S2VybiwgTGlzYQ==|https://frl.publisso.de/adhoc/uri/SmFraSwgTGVuYQ==|https://frl.publisso.de/adhoc/uri/UnVzaWdudW9sbywgR2l1c2VwcGU=|https://frl.publisso.de/adhoc/uri/TWVydGlucywgU3VzYW5uZQ==|https://frl.publisso.de/adhoc/uri/U29tb2d5aSwgVml2aWVu|https://frl.publisso.de/adhoc/uri/TmV1bWFubi1IYWVmZWxpbiwgQ2hyaXN0b3Bo|https://frl.publisso.de/adhoc/uri/VHJpbmttYW5uLCBGcmVkZXJpaw==|https://frl.publisso.de/adhoc/uri/TcO8bGxlciwgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/VGhpbW1lLCBSb2JlcnQ=|https://frl.publisso.de/adhoc/uri/VW1oYXUsIE1hcmt1cw==|https://frl.publisso.de/adhoc/uri/UXVpbnRpLCBJc2FiZWxsYQ==|https://frl.publisso.de/adhoc/uri/V2FnbmVyLCBEaXJr|https://frl.publisso.de/adhoc/uri/UGFubmluZywgTWFyY3Vz|https://frl.publisso.de/adhoc/uri/Q3VubmluZ2hhbS1SdW5kbGVzLCBDaGFybG90dGU=|https://frl.publisso.de/adhoc/uri/TGF1Ym5lciwgS2F0aGFyaW5h|https://orcid.org/0000-0002-1172-865X
1000 Hinweis
  • DeepGreen-ID: a4e51b115fda430dabc0a578cb8bb947 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6446023.rdf
1000 Erstellt am 2023-04-28T11:57:44.350+0200
1000 Erstellt von 322
1000 beschreibt frl:6446023
1000 Zuletzt bearbeitet 2023-10-20T17:24:41.112+0200
1000 Objekt bearb. Fri Oct 20 17:24:41 CEST 2023
1000 Vgl. frl:6446023
1000 Oai Id
  1. oai:frl.publisso.de:frl:6446023 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source